Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
PARSIPPANY, N.J., Feb. 11, 2016 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s fourth quarter and year ended December 31, 2015 will be released before the market opens on Thursday, February 25, 2016. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, February 25, 2016, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) ten minutes prior to the start of the call and providing the Conference ID 93538831.
A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and providing the Conference ID 93538831. The replay of the call will be available for two weeks from the date of the live call.
The live, listen-only webcast of the conference call can also be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the call.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Investor Contact: Pacira Pharmaceuticals, Inc. Jessica Cho, (973) 254-3574 [email protected]
